Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters

Seder, Christopher W.; Arndt, Andrew; Jordano, Lia; Basu, Sanjib; Fhied, Cristina; Sayidine, Selina; Chmielewski, Gary W.; Gallo, Kelsey; Liptay, Michael J.; Borgia, Jeffrey A.

doi:10.1016/j.athoracsur.2017.06.036

Cited by 10 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of the biomarker discovery research conducted in recent years has been devoted to the analysis of biomarkers isolated from serum or plasma, thanks to the fact that blood sampling can be carried out following a highly standardized method, reproducible, easy to perform worldwide, which is also applicable to the longitudinal analysis of samples, for tumor recurrence monitoring. [90] However, plasma proteomics represents a formidable task, due to the high complexity and extreme dynamic range of the proteins present in plasma (up to 10 11 ). In addition, a few proteins at very high concentrations are present (primarily albumin, which alone represents more than half of the total protein content of plasma), which mask low abundance proteins that may be differentially regulated and potentially disease-relevant.…”

Section: Biological Sample Typementioning

confidence: 99%

Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

Gasparri

Sedda

Noberini

et al. 2020

Proteomics Clinical Apps

View full text Add to dashboard Cite

The current knowledge on proteomic biomarker analysis for the early diagnosis of lung cancer is summarized, underlining the diversity among the results and the current interest in translating research results into clinical practice. A MEDLINE/PubMed literature search to retrieve all the papers published in the last 10 years is performed. Proteomics studies on lung cancer have gathered evidence on the potential role of biomarkers in early diagnosis. Although promising, none of them have proved to be sufficiently reliable to achieve validation. Future research should evolve toward a multipanel analysis of proteins, considering the possibility that individual biomarkers might not be specific enough to diagnose lung cancer, but could be related to oncological conditions.

show abstract

Section: Biological Sample Typementioning

confidence: 99%

Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

Gasparri

Sedda

Noberini

et al. 2020

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…The associations of PRL and development of various cancer has been evaluated in breast, prostate, colorectal, gynecological, and hepatocellular cancer ( Goffin, 2017 ). Only a few studies have examined the relationship between the PRL levels and lung cancer ( Caponnetto et al, 2017 ; Seder et al, 2017 ). PRL was introduced in a seven-analyte panel of lung cancer biomarkers for the first time and the panel was suggested useful to risk stratify cancer patients for early recurrence after resection of node-negative NSCLC less than 4 cm ( Seder et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis

et al. 2018

View full text Add to dashboard Cite

Introduction: Lung cancer ranks top in the cause of cancer death globally. The identification of effective biomarkers is essential for non-small cell lung cancer (NSCLC) diagnosis.Methods: The expression levels of prolactin (PRL), CEA, and CYFR21 in serum were assayed by ELISA. The blood samples were attained from 44 NSCLC cases and 44 healthy controls. Logistic regression and receiver operating characteristic (ROC) analyses were applied to evaluate the diagnostic efficacy and create diagnostic mathematical models.Results: Serum PRL, CEA, and CYFR21 levels were significantly higher in patients with NSCLC than the healthy controls (all P-values <0.001). According to the model to predict NSCLC patients from the healthy controls, a combination of PRL, CEA, and CYFR21 biomarkers was more effective than individual biomarker alone, with AUC = 0.960 (95% CI: 0.921–0.999), sensitivity = 0.909, specificity = 0.955, positive predicted value = 0.952, and negative predicted value = 0.913.Conclusion: Prolactin can be used as a potential serum biomarker for the diagnosis of NSCLC. A panel of PRL, CEA, and CYFRA21 was found as promising serum biomarkers for the diagnosis of NSCLC with relatively high sensitivity and specificity.

show abstract

“…Recently, Seder et al. reported that both b-HCG and prolactin might be useful serum biomarkers for identifying patients with higher probability of NSCLC recurrence after initial excision [7]. We present a rare case of a male patient with lung cancer, appearing with gynecomastia causing mastodynia and galactorrhea as initial symptoms.…”

Section: Introductionmentioning

confidence: 93%

Galactorrhea, mastodynia and gynecomastia as the first manifestation of lung adenocarcinoma. A case report

Lazopoulos

Krimiotis

Schizas

et al. 2019

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Gynecomastia with mastodynia and galactorrhea as a paraneoplastic syndrome due to lung cancer with complete response after surgical excision is rare.A 62-year-old Caucasian male presented with mastodynia, galactorrhea and right breast enlargement. Chest x-ray revealed a left upper lobe tumor. The patient had high levels of serum beta-human chorionic gonadotropin (b-HCG) and prolactine. Complete staging was negative for metastases.A typical left upper lobectomy with radical mediastinal lymph node dissection was performed. Pathology report was consistent with a poorly differentiated adenocarcinoma (T2N1M0). Immunohistochemically, multinucleate cells and occasional mononucleate tumor cells showed positivity for human chorionic gonadotropin.The patient received adjuvant chemotherapy with cisplatin – navelbine. One year later physical examination showed regression of both gynecomastia and mastodynia and there was no nipple discharge, while he is free from local or distant metastatic disease and the b-HCG level is normal (1,59 mIU/ml).This case represents a very rare, first manifestation of lung cancer. Galactorrhea, mastodynia and gynecomastia were the initial symptoms, which totally resolved following the successful surgical resection and adjuvant chemotherapy. In this case, prolactin and b-HCG are useful biomarkers during follow up for checking local or distal recurrence of the disease.

show abstract

Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters

Abstract: Serum-based biomarkers may be useful for risk stratifying patients with node-negative NSCLC less than 4 cm for recurrence after lung resection.

Cited by 10 publications

References 27 publications

Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis

Galactorrhea, mastodynia and gynecomastia as the first manifestation of lung adenocarcinoma. A case report

Contact Info

Product

Resources

About